First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
growth - The 37.6% revenue growth, asset-light royalty model, and exposure to high-growth oncology/immunology markets attract growth…
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for high-growth…
Watch on earnings: Quarterly royalty revenue by partner product (Darzalex Faspro, Phesgo, Herceptin SC sales trends), Number of active ENHANZE collaboration targets in clinical development and regulatory review, Partner product market share in subcutaneous vs intravenous formulations within therapeutic categories.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $1.8B to $2.0B as commercial performance of key enhanze-enabled partner products, particularly darzalex faspro (janssen) and phesgo.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.